Next 10 |
home / stock / azn / azn articles
In its upcoming report, Astrazeneca (NYSE: AZN) is predicted by Wall Street analysts to post quarterly earnings of $0.95 per share, reflecting a de...
As the market runs into rough weather, the importance of the upcoming week’s earnings cannot be emphasized enough. A lot is riding on the ear...
Drug shortages in the UK have more than doubled between 2020 and 2023, a recent study by the Nuffield Trust reveals. Brexit is cited as a significa...
AstraZeneca Plc (NASDAQ:AZN) released updated exploratory results from the TOPAZ-1 Phase 3 trial of Imfinzi (durvalumab) i...
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has determined that there is no substantial evid...
Thursday, AstraZeneca Plc (NASDAQ:AZN) raised its annualized dividend for 2024 by $0.20 to $3.10 per share, underlining the com...
On Friday, the FDA approved Daiichi Sankyo Ltd’s (OTC:DSKYF) (OTC:DSNKY) and AstraZeneca Plc’s (NASDAQ:AZN) Enhertu...
As the weekend comes to a close, let’s take a look at the top stories that shaped the week. From the U.S. manufacturing sector hitting an 18-...
Friday, AstraZeneca Plc (NASDAQ:AZN) released high-level results of the ADRIATIC Phase 3 trial of Imfinzi monotherapy and Imfinzi plus Im...
News, Short Squeeze, Breakout and More Instantly...
AstraZeneca PLC Company Name:
AZN Stock Symbol:
NYSE Market:
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery AstraZeneca: Revenue and EPS summary Financial performance for Q1 2024 (Growth numbers at CER) Total Revenue up 19% to $12,679m, driven by an 18% increase in Product Sal...
In its upcoming report, Astrazeneca (NYSE: AZN) is predicted by Wall Street analysts to post quarterly earnings of $0.95 per share, reflecting a de...
As the market runs into rough weather, the importance of the upcoming week’s earnings cannot be emphasized enough. A lot is riding on the ear...